The Board of Directors of Vera Salus Ricerca has voted in favour of the incorporation of FlavOncology in Switzerland with a dedicated, strong executive team comprising a mix of local entrepreneurs and key figures from the company’s shareholders.

The management of Vera Salus Ricerca Srl (VSR) has decided unanimously to continue FlavOncology’s development in Switzerland, recognizing the fertile ecosystem present in that country amenable to pharma growth and success. VSR is committed to incorporate a NewCo dedicated to FlavOncology in the canton of Valais (Switzerland), relying on BioArk and the Ark Foundation for support and collaboration. The NewCo is intended to kick-off in early 2021 with a dedicated team of executives selected from swiss and VSR key professionals, that will launch an aggressive fundraising campaign to implement FlavOncology’s business plan.